SCHEMBL14949020

SCHEMBL14949020

CCc1c[nH]cc(-c2ccc(F)cc2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
BRD4 O60885 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
PRKCZ Q05513 1/20 0.35
PTGS2 P35354 3/20 0.34
NR4A2 P43354 1/20 0.34
CHRNA7 P36544 2/20 0.34
RAB9A P51151 1/20 0.34
GCGR P47871 1/20 0.34
MAPK14 Q16539 1/20 0.34
ALDH1A1 P00352 2/20 0.34
POLB P06746 1/20 0.34
LTB4R Q15722 1/20 0.33
LTB4R2 Q9NPC1 1/20 0.33
PGR P06401 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CDC7 O00311 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28319846 0.87 SLC6A4 (0.38) MAPTSLC6A4SLC6A3PRKCZPTGS2
SCHEMBL23158698 0.86 NR4A2 (0.38) SLC6A4SLC6A3NR4A2RAB9AALDH1A1
SCHEMBL28199937 0.85 NR4A2 (0.33) MAPTBRD4SLC6A4SLC6A3NR4A2
SCHEMBL20351754 0.79 BRD4 (0.40) MAPTBRD4SLC6A4SLC6A3PTGS2
SCHEMBL28199967 0.75 GRM2 (0.36) MAPTBRD4SLC6A4SLC6A3PTGS2
SCHEMBL18031340 0.75 NR4A2 (0.40) MAPTBRD4SLC6A4SLC6A3PTGS2
SCHEMBL17233734 0.75 AURKB (0.42) BRD4SLC6A4SLC6A3MAPK14ALDH1A1
SCHEMBL24878447 0.75 MET (0.38) MAPTBRD4PTGS2CHRNA7MAPK14
SCHEMBL10396846 0.74 NR4A2 (0.47) MAPTSLC6A4SLC6A3PTGS2NR4A2
SCHEMBL699308 0.74 PRKCZ (0.49) MAPTPRKCZRAB9AGCGRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors BETTA PHARMACEUTICALS CO., LTD. (CN) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors MET, RET, ABL1 MAPT 3288/4885BRD4 1414/4885SLC6A4 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.